Judith Braun-Davis

Product managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.

Implementation of policies that respond to industry compliance standards poses a considerable burden for companies in terms of time and expense. Unless industry changes its response to state laws, the condition will worsen.